http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-371781-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e18faf9096d8ad33baaf2439e952ea75
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
filingDate 2002-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d12335890578ddb121c7e66d80cc8a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e5423832b05dd46d29894ed46a3185e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a75f9857f783e1ce906a76c05d47d7cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2ca9d119289dc78712589215ec05f40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e864a0ce44114d65f10bd8e7ebe48461
publicationDate 2005-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PL-371781-A1
titleOfInvention G-CSF conjugates
abstract Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.
priorityDate 2001-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25610
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID608246
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP97712
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP09920
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP09919
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO02837
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396839
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281096
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396425
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID12985
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1440
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO02708
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35834
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35833
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ28746

Total number of triples: 44.